Guidance on the new policy from the Department for Science, Innovation and Technology (DSIT) notes that qualifying for ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new ...

23andMe was founded 19 years ago to provide saliva-based genetic testing of health and ancestry to consumers, going public in ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The partner of former Theranos founder and chief executive Elizabeth Holmes, Billy Evans, has reportedly raised millions of ...

In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...

BioMarin has been resetting its business with cuts in headcount and a narrowing of active programmes over the last year or so ...

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...